![](https://ml-eu.globenewswire.com/media/ad72e873-4396-45eb-aca2-bfe1d57a423d/small/certa-png.png)
Certa Therapeutics Receives EU Orphan Designation for FT011, a GPR68 Inhibitor Being Developed as an Anti-Fibrotic ...
MELBOURNE, Australia, July 22, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the European Medicines Agency ( …